Your browser does not support JavaScript!

205, Al Qaizi Building, Al Muteena Street, Deira 40192 AE
JollyRX
205, Al Qaizi Building, Al Muteena Street, Deira , AE
+918003633988 https://cdn1.storehippo.com/s/6052eead9e1cf8aa024c48c8/606ecab786617735b12707ae/webp/jollyrx-480x480.png" contact@jollyrx.com
61b191cbc32770d90fd313cb HARVONI 90/400 MG 28 TAB. https://cdn1.storehippo.com/s/6052eead9e1cf8aa024c48c8/61b1911e6641ecd531928211/webp/harvoni-90-400-mg-28-tab-.jpg

What is Harvoni and how is it used?

Harvoni is a prescription medicine used to treat the symptoms of Hepatitis C Virus Infection. Harvoni may be used alone or with other medications.

Harvoni belongs to a class of drugs called HCV NS5A Inhibitors; HCV Polymerase Inhibitors.

It is not known if Harvoni is safe and effective in children younger than 3 years of age.

What are the possible side effects of Harvoni?

Harvoni may cause serious side effects including:

  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • right-sided upper stomach pain,
  • vomiting,
  • loss of appetite,
  • yellowing of the skin or eyes (jaundice), and
  • general feeling of unwellness  

Get medical help right away, if you have any of the symptoms listed above.

The most common side effects of Harvoni include:

  • weakness,
  • headache, and
  • tired feeling

Tell the doctor if you have any side effect that bothers you or that does not go away.

DESCRIPTION

HARVONI is a fixed-dose combination tablet containing ledipasvir and sofosbuvir for oral administration. Ledipasvir is an HCV NS5A inhibitor and sofosbuvir is a nucleotide analog inhibitor of HCV NS5B polymerase.

Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir. The tablets include the following inactive ingredients: colloidal silicon dioxide, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing the following inactive ingredients: FD&C yellow #6/sunset yellow FCF aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

Ledipasvir

The IUPAC name for ledipasvir is Methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate.

It has a molecular formula of C49H54F2N8O6 and a molecular weight of 889.00. It has the following structural formula:

Ledipasvir -  Structural Formula Illustration

Ledipasvir is practically insoluble (less than 0.1 mg/mL) across the pH range of 3.0-7.5 and is slightly soluble below pH 2.3 (1.1 mg/mL).

Sofosbuvir

The IUPAC name for sofosbuvir is (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate. It has a molecular formula of C22H29FN3O9P and a molecular weight of 529.45. It has the following structural formula:

Sofosbuvir - Structural Formula Illustration

Sofosbuvir is a white to off-white crystalline solid with a solubility of at least 2 mg/mL across the pH range of 2-7.7 at 37oC and is slightly soluble in water.

INDICATIONS

HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see DOSAGE AND ADMINISTRATION and Clinical Studies]:

  • genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
  • genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin
  • genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin

Storage And Handling

Tablets

HARVONI tablets 90 mg/400 mg are orange, diamond-shaped, film-coated, debossed with "GSI" on one side and "7985" on the other side of the tablet. Each bottle contains 28 tablets (NDC 61958-1801-1), a silica gel desiccant and polyester coil, and is closed with a child-resistant closure.

HARVONI tablets, 45 mg/200 mg, are white, capsule-shaped, film-coated, debossed with "GSI" on one side and "HRV" on the other side of the tablet. Each bottle contains 28 tablets (NDC 61958-1803-1), a silica gel desiccant and polyester coil, and is closed with a child-resistant closure.

  • Store below 30 °C (86 °F).
  • Dispense only in original container.
  • Do not use if seal over bottle opening is broken or missing.

SKU-ZQQME5HP3M05
in stock INR 100
1 1

HARVONI 90/400 MG 28 TAB.

₹100


Sold By: jollyrx
VARIANT SELLER PRICE QUANTITY

Description of product

What is Harvoni and how is it used?

Harvoni is a prescription medicine used to treat the symptoms of Hepatitis C Virus Infection. Harvoni may be used alone or with other medications.

Harvoni belongs to a class of drugs called HCV NS5A Inhibitors; HCV Polymerase Inhibitors.

It is not known if Harvoni is safe and effective in children younger than 3 years of age.

What are the possible side effects of Harvoni?

Harvoni may cause serious side effects including:

  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • right-sided upper stomach pain,
  • vomiting,
  • loss of appetite,
  • yellowing of the skin or eyes (jaundice), and
  • general feeling of unwellness  

Get medical help right away, if you have any of the symptoms listed above.

The most common side effects of Harvoni include:

  • weakness,
  • headache, and
  • tired feeling

Tell the doctor if you have any side effect that bothers you or that does not go away.

DESCRIPTION

HARVONI is a fixed-dose combination tablet containing ledipasvir and sofosbuvir for oral administration. Ledipasvir is an HCV NS5A inhibitor and sofosbuvir is a nucleotide analog inhibitor of HCV NS5B polymerase.

Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir. The tablets include the following inactive ingredients: colloidal silicon dioxide, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing the following inactive ingredients: FD&C yellow #6/sunset yellow FCF aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

Ledipasvir

The IUPAC name for ledipasvir is Methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate.

It has a molecular formula of C49H54F2N8O6 and a molecular weight of 889.00. It has the following structural formula:

Ledipasvir -  Structural Formula Illustration

Ledipasvir is practically insoluble (less than 0.1 mg/mL) across the pH range of 3.0-7.5 and is slightly soluble below pH 2.3 (1.1 mg/mL).

Sofosbuvir

The IUPAC name for sofosbuvir is (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate. It has a molecular formula of C22H29FN3O9P and a molecular weight of 529.45. It has the following structural formula:

Sofosbuvir - Structural Formula Illustration

Sofosbuvir is a white to off-white crystalline solid with a solubility of at least 2 mg/mL across the pH range of 2-7.7 at 37oC and is slightly soluble in water.

INDICATIONS

HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see DOSAGE AND ADMINISTRATION and Clinical Studies]:

  • genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
  • genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin
  • genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin

Storage And Handling

Tablets

HARVONI tablets 90 mg/400 mg are orange, diamond-shaped, film-coated, debossed with "GSI" on one side and "7985" on the other side of the tablet. Each bottle contains 28 tablets (NDC 61958-1801-1), a silica gel desiccant and polyester coil, and is closed with a child-resistant closure.

HARVONI tablets, 45 mg/200 mg, are white, capsule-shaped, film-coated, debossed with "GSI" on one side and "HRV" on the other side of the tablet. Each bottle contains 28 tablets (NDC 61958-1803-1), a silica gel desiccant and polyester coil, and is closed with a child-resistant closure.

  • Store below 30 °C (86 °F).
  • Dispense only in original container.
  • Do not use if seal over bottle opening is broken or missing.

User reviews

  0/5